• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ECMOHO Is Trading Lower By 29%; Here Are 28 Stocks Moving Premarket

    9/21/22 6:16:48 AM ET
    $ACRX
    $AGRI
    $AIM
    $AMPE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Metal Fabrications
    Industrials
    Get the next $ACRX alert in real time by email

    Gainers

    • Ampio Pharmaceuticals, Inc. (NYSE:AMPE) rose 17.8% to $0.0942 in pre-market trading after declining around 5% on Tuesday.
    • AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) shares rose 14.2% to $1.93 in pre-market trading. AgriFORCE recently announced the launch of un(Think) Awakened Flour.
    • Edgio, Inc. (NASDAQ:EGIO) rose 13.1% to $3.45 in pre-market trading. Edgio reported the completion of its most successful week by setting all-time traffic record.
    • Ra Medical Systems, Inc. (NYSE:RMED) rose 12.7% to $0.1601 in pre-market trading after the company reported results of its special meeting of stockholders and a 1-for-50 reverse stock split.
    • Smart for Life, Inc. (NASDAQ:SMFL) rose 12.6% to $0.5150 in pre-market trading after declining around 5% on Tuesday.
    • AMTD Digital Inc. (NYSE:HKD) rose 12.5% to $81.60 in pre-market trading after dropping 21% on Tuesday.
    • FOXO Technologies Inc. (NYSE:FOXO) rose 10.9% to $2.34 in pre-market trading after dropping over 15% on Tuesday.
    • AIM ImmunoTech Inc. (NYSE:AIM) rose 9.1% to $0.67 in pre-market trading.
    • Windtree Therapeutics, Inc. (NASDAQ:WINT) rose 9% to $0.3609 in pre-market trading. WindTree, last month, entered into a global licensing agreement for the development and commercialization of KL4 surfactant and AEROSURF.
    • Digital World Acquisition Corp. (NASDAQ:DWAC) rose 8.8% to $20.25 in pre-market trading. Digital World Acquisition shares dropped 17% on Tuesday following an FT report suggesting investors in the SPAC are pushing for better terms in a financing package.
    • Getty Images Holdings, Inc. (NYSE:GETY) rose 7.4% to $8.90 in pre-market trading. Macquarie, on Tuesday, initiated coverage on Getty Images with a Neutral rating and announced a price target of $8.25.
    • VistaGen Therapeutics, Inc. (NASDAQ:VTGN) rose 8% to $0.1860 in pre-market trading after declining around 5% on Tuesday.
    • Pagaya Technologies Ltd. (NASDAQ:PGY) rose 7.8% to $2.47 in pre-market trading after dropping 67% on Tuesday.
    • Paysafe Limited (NYSE:PSFE) rose 7.7% to $1.67 in pre-market trading. Paysafe disclosed a new partnership with Spreedly to offer Paysafe’s payment gateway to Spreedly’s international merchant base.
    • China Liberal Education Holdings Limited (NASDAQ:CLEU) rose 7.7% to $0.9850 in pre-market trading after surging 13% on Tuesday.

     

    Don’t forget to check out our premarket coverage here .

    Losers

    • ECMOHO Limited (NASDAQ:MOHO) fell 29.1% to $0.0822 in pre-market trading after the company said it received delisting notice from the Nasdaq.
    • SOBR Safe, Inc. (NASDAQ:SOBR) fell 24.9% to $2.29 in pre-market trading. SOBR Safe shares jumped around 233% on Tuesday following a report suggesting The National Transportation Safety Board is recommending that NHTSA require passive alcohol-detection systems.
    • Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) fell 20.5% to $1.75 in pre-market trading after jumping over 60% on Tuesday.
    • Ventoux CCM Acquisition Corp. (NASDAQ:VTAQ) fell 12.4% to $5.35 in pre-market trading after declining 13% on Tuesday.
    • Smith Micro Software, Inc. (NASDAQ:SMSI) shares fell 11.9% to $2.37 in pre-market trading.
    • Amprius Technologies, Inc. (NYSE:AMPX) shares fell 10.8% to $9.81 in pre-market trading after jumping 86% on Tuesday.
    • Stitch Fix, Inc. (NASDAQ:SFIX) fell 10% to $4.25 in pre-market trading as the company reported a wider-than-expected loss for its fourth quarter and issued weak Q1 sales guidance.
    • NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) fell 9.8% to $18.75 in pre-market trading after jumping around 42% on Tuesday.
    • Fast Radius, Inc. (NASDAQ:FSRD) shares fell 8.3% to $0.4111 in pre-market trading after gaining around 7% on Tuesday.
    • bluebird bio, Inc. (NASDAQ:BLUE) fell 7.8% to $6.32 in pre-market trading. bluebird bio shares jumped over 15% on Tuesday after Raymond James maintained an Outperform rating on the stock and raised its price target from $8 to $10.
    • Zovio Inc (NASDAQ:ZVO) fell 7.4% to $0.1808 in pre-market trading.
    • AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) fell 6.8% to $0.2369 in pre-market trading. AcelRx Pharmaceuticals, last month, posted a Q2 loss of $0.06 per share.
    • Sunrun Inc. (NASDAQ:RUN) fell 5.3% to $32.60 in pre-market trading after dropping 7% on Tuesday.
    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $AGRI
    $AIM
    $AMPE

    CompanyDatePrice TargetRatingAnalyst
    Sunrun Inc.
    $RUN
    1/13/2026Mkt Perform
    Raymond James
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    Sunrun Inc.
    $RUN
    11/10/2025$27.00Neutral → Buy
    Guggenheim
    Sunrun Inc.
    $RUN
    11/7/2025$22.00 → $23.00Buy
    TD Cowen
    Sunrun Inc.
    $RUN
    10/21/2025$26.00Neutral → Buy
    Citigroup
    More analyst ratings

    $ACRX
    $AGRI
    $AIM
    $AMPE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Sunrun

    Raymond James initiated coverage of Sunrun with a rating of Mkt Perform

    1/13/26 9:17:53 AM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Maxim Group

    Maxim Group downgraded VistaGen from Buy to Hold

    12/17/25 12:23:57 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $AGRI
    $AIM
    $AMPE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

    This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the "Rights Of

    2/12/26 4:35:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

    Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will participate in a Virtual Investor Closing Bell Event on Thursday, February 19, 2026, at 4:00 PM ET. Equels will focus on AIM's clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing DURIPANC clinical trial in collaboration with AstraZeneca combining Ampligen and AstraZeneca

    2/12/26 8:55:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $AGRI
    $AIM
    $AMPE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $AGRI
    $AIM
    $AMPE
    SEC Filings

    View All

    SEC Form ABS-15G filed by Sunrun Inc.

    ABS-15G - Sunrun Inc. (0001469367) (Filer)

    2/13/26 1:09:42 PM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    SEC Form 10-Q filed by Vistagen Therapeutics Inc.

    10-Q - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    2/12/26 4:38:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    2/12/26 4:35:48 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $AGRI
    $AIM
    $AMPE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Welch David Ryan was granted 97,410 shares and bought $1,424 worth of shares (11 units at $129.42), increasing direct ownership by 647% to 97,421 units (SEC Form 4)

    4 - AGRIFORCE GROWING SYSTEMS LTD. (0001826397) (Issuer)

    9/30/25 7:56:59 PM ET
    $AGRI
    Metal Fabrications
    Industrials

    Director Fenster Edward Harris bought $543,500 worth of shares (50,000 units at $10.87), increasing direct ownership by 4% to 1,408,182 units (SEC Form 4)

    4 - Sunrun Inc. (0001469367) (Issuer)

    5/13/25 7:57:16 AM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:16 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $AGRI
    $AIM
    $AMPE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fenster Edward Harris gifted 25,000 shares, exercised 250,600 shares at a strike of $5.08 and sold $3,269,222 worth of shares (163,844 units at $19.95), increasing direct ownership by 4% to 1,553,895 units (SEC Form 4)

    4 - Sunrun Inc. (0001469367) (Issuer)

    2/12/26 5:21:57 PM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    Director Chemerow David I. was granted 2,800 shares (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    2/6/26 5:03:20 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by President and CEO Smith William W Jr

    4 - SMITH MICRO SOFTWARE, INC. (0000948708) (Issuer)

    2/5/26 5:37:33 PM ET
    $SMSI
    Computer Software: Prepackaged Software
    Technology

    $ACRX
    $AGRI
    $AIM
    $AMPE
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Sunrun Announces Appointment of Craig Cornelius to its Board of Directors

    SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sunrun (NASDAQ:RUN), America's largest provider of home battery storage, solar, and home-to-grid power plants, today announced the appointment of Craig Cornelius as a member of Sunrun's board of directors (the "Board"). Mr. Cornelius brings two decades of industry experience across the renewable energy space. "I am excited to announce the appointment of Craig as our newest board member. Craig brings a wealth of experience and perspective, having led large, complex energy development, operations and ownership businesses in the energy sector," said Sunrun CEO Mary Powell. "I'm confident that his insights will be valuable as we continue to lea

    11/6/25 4:02:00 PM ET
    $RUN
    Industrial Machinery/Components
    Miscellaneous

    Vistagen Appoints Paul Edick to its Board of Directors

    Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,

    10/29/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $AGRI
    $AIM
    $AMPE
    Financials

    Live finance-specific insights

    View All

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pagaya Reports Fourth Quarter and Full Year Ended 2025 Results

    Reported solid performance across all key metrics: $34 million GAAP Net income; up $272 million YoY $98 million Adjusted EBITDA; up 53% YoY $335 million Total revenue and other income; up 20% YoY $2.7 billion Network volume; up 3% YoY Pagaya Technologies Ltd. (NASDAQ:PGY) ("Pagaya", the "Company" or "we"), a global technology company delivering artificial intelligence infrastructure for the financial ecosystem, today announced financial results for the fourth quarter and full year ended 2025. For additional information, view Pagaya's fourth quarter 2025 letter to shareholders here. "Our fourth quarter and full-year results demonstrate, again, the benefits of years of w

    2/9/26 7:03:00 AM ET
    $PGY
    Finance: Consumer Services
    Finance

    Paysafe to Release Fourth Quarter and Full Year 2025 Earnings Results on March 3

    Paysafe Limited (NYSE:PSFE), a global payments platform, will announce fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before market open. Management will host a live webcast to discuss the results at 8:30a.m. ET the same day. The webcast, along with supplemental information, can be accessed on the investor relations section of the Paysafe website at ir.paysafe.com. An archive will be available after the conclusion of the event and will remain available via the same link for at least one year. Webcast and Conference Call Information: Time: Tuesday, March 3, 2026, at 8:30 a.m. ET Webcast: Go to the Investor Relations section of t

    2/5/26 8:30:00 AM ET
    $PSFE
    Real Estate

    $ACRX
    $AGRI
    $AIM
    $AMPE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Paysafe Limited

    SC 13D/A - Paysafe Ltd (0001833835) (Subject)

    11/25/24 5:15:35 PM ET
    $PSFE
    Real Estate

    Amendment: SEC Form SC 13D/A filed by Getty Images Holdings Inc.

    SC 13D/A - Getty Images Holdings, Inc. (0001898496) (Subject)

    11/22/24 5:10:10 PM ET
    $GETY
    Real Estate